Why join the PERMIDES platform? It is where you can find your biopharma-IT match.
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 367 entries.
Entries by oslocancer
Åtte elever fra Ullern videregående skole har denne uken vært på utplassering hos avdeling for patologi ved Oslo universitetssykehus. Morsomt har det vært, og Marie Wahlstrøm kan godt tenke seg å bli patolog.
Targovax ASA’s shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. Targovax is a clinical stage company, developing immuno-oncology therapies to target treatment-resistant solid tumors.
The first call for proposals for the PERMIDES project is opening on March 15th. We urge all small and medium sized biopharma-companies working to take the step into the digital era: Apply for funding up to 60 000 Euros.
Nordic Mentor Network for Entrepreneurship (NOME) is an elite Nordic mentoring program for promising life science projects and startups with world class mentors.
Oslo Cancer Cluster member BerGenBio enters collaboration with MSD focused on clinical evaluation of BGB324 in combination with KEYTRUDA® (pembrolizumab) in advanced lung and breast cancer.
We are currently looking for an EU advisor with skills and experience in writing EU funding proposals. This is a fixed term contract with duration to the end of 2018.
IRW Consulting, Eisai and Personalis, Inc. are all new members of the Oslo Cancer Cluster. Please read more about them here.
De nordiske landene bør samarbeide mer for å utvikle bedre kreftbehandlinger. Sammen kan Norden bli et globalt forsknings- og testsenter for nye kreftbehandlinger og -medisiner. Det kan gi store gevinster for kreftpasienter i hele verden. Denne kronikken sto på trykk i Aftenposten torsdag 9. mars. Ketil Widerberg, daglig leder i Oslo Cancer Cluster, skrev kronikken samme uke som The Economist, Forskningsrådet og […]
Oslo, Norway, 6 March 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:
– 10th European Life Science CEO Forum
– Redeye – Fight Cancer Seminar
– 11th Annual BIO-Equity Spring 2017 Conference
Oslo Cancer Cluster has a new Head of Communications. She wants to help you reach out.
Oslo Cancer Cluster member Radium Hospital Research Foundation, Radforsk, has launched their own podcast. The podcast is named Radium, and is about cancer research and development of new cancer treatments, as well as updates on Radforsk´s portfolio companies.
Oslo, Norway, 16 February 2017 – Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results.
A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).
Are you a startup or entrepreneur in Healthcare or Life-Sciences? If yes – keep reading!
Oslo Cancer Cluster member Photocure ASA reported that full year 2016 revenues ended at NOK 143.6 million (134.7). Photocure targets revenues from the US operations to quadruple to a range of USD 15 million by 2020.
Cancer Crosslinks is now one of the most relevant meetings for Norwegian oncologists, with 300 delegates attending this year. You may download the presentations here.
Oslo Cancer Cluster is proud to be partner of the Economist Events War On Cancer Nordics. The event will gather leaders in oncology from the Nordic region and beyond, to discuss the region’s primary challenges in cancer care and control.
Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis.
The Norwegian Research Council recently granted funding to Oslo Cancer Cluster members; BerGen Bio, Bionor Immuno, GE Healthcare, Lytix Biopharma, PCI Biotech and Phoenix Solutions.
Oslo Cancer Cluster member Targovax will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017.
Lytix Biopharma, a clinical-stage biopharmaceutical company developing novel cancer immune therapies, has been awarded a NOK 15.9 million grant from The Norwegian Research Council (User-driven Research-based Innovation) to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC).
Survival rate of 68% from first patient cohort vs published historical rate of 30-53% suggests signal of clinical efficacy for the drug candidate. Full data set from first patient cohort to be submitted for presentation at ASCO annual meeting in June.
Oslo Cancer Cluster member Lytix Biopharma has been awarded a NOK 15.9 million grant from The Norwegian Research Council.
Our member PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”.
Cancer Crosslinks 2017 on January 26 features a really interesting program with International and Norwegian thought leaders presenting recent findings within cancer research.
PCI Biotech, Ultimovacs, Arctic Pharma, Oncoimmunity and Myhere have been granted funding to develop improved cancer treatments through collaborative projects.
Dehns Patent and Trade Mark Attorneys recently joined the Oslo Cancer Cluster. Dehns is one of Europe’s largest firms of patent and trade mark attorneys and has a 40 year history of working with Norwegian organisations such as: Dynal, Inven2,Lytix Biopharma, Nextera, NMBU, NTNU, Nycomed, PCI Biotech and Photocure. As members, our aim is to […]
The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway
The immune oncology company Lytix Biopharma AS has enrolled the first patient in the Phase 1 study of LTX-315 in combination with immune checkpoint inhibitors (ICIs). Since LTX-315 turns immunogenically “cold” tumours “hot” it may be an ideal combination with other immunotherapies.
The Board of Directors of Phoenix Solutions is pleased to announce that the company has completed a series A financing led by a small group of healthcare angel investors.
Prime Minister Erna Solberg stated in her speech that Oslo Cancer Cluster´s financing in the future is secured by the Research Council.
Anne Lise Ryel, General Secretary of the Norwegian Cancer Society gave a powerful speech at the celebration of Oslo Cancer Cluster´s 10 years anniversary. Here she stresses the importance of collaboration and ensures the continued support to the cluster.
Oslo Cancer Cluster member Vaccibody succesfully raised NOK 220 million (€ 24 million). The Private Placement was significantly oversubscribed by both existing shareholders and new investors.
Nordic Nanovector has raised MNOK 500 in gross proceeds through a private placement of 4,374,244 new shares.
Gjennom det skolefaglige samarbeidet mellom Oslo Cancer Cluster og Ullern videregående skole har realfagselever hatt en ukes utplassering på avdeling for tumorbiologi ved Institutt for Kreftforskning ved Oslo universitetssykehus i syv år.
Nordic Nanovector presented the updated results from its ongoing Lymrit 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed non-Hodgkin lymphoma (NHL) at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA).
Photocure ASA (OSE:PHO) announced today that new 2016 French National Guidelines for the management of Bladder Cancer includes its Blue Light Cystoscopy (BLC) with Hexvix®.
Oslo Cancer Cluster member Photocure reported a revenue growth of 17 % to NOK 31.6 million in the third quarter of 2016 for the Hexvix/Cysview commercial franchise.
Cancer Crosslinks er den årlige møteplassen innen onkologi og hematologi, og det er med stor glede vi inviterer onkologer, hematologer og forskere til det niende Cancer Crosslinks i vår egen Oslo Cancer Cluster Innovasjonspark 26. januar 2017.
This composition of matter patent protects Targovax’s lead product from its ONCOS platform, the oncolytic viral product ONCOS-102 and expires in 2029. A US patent covering ONCOS-102 was granted in May 2016.
The biopharmaceutical industry is at a frenzy to develop innovative drugs for cancer. No wonder, when the market size is estimated to over 800 BNOK in 2020, the population world-wide is getting older and the incidence and prevalence of cancer is increasing.
Nordic Nanovector ASA will present the therapeutic effect of combined treatment with Betalutin® and rituximab in a preclinical model of non-Hodgkin lymphoma at the 58th Annual American Society of Hematology (ASH).
Oslo Cancer Cluster member PCI Biotech has initiated a process with the objective to carry out a share issue in the range of NOK 40-50 million by the end of November 2016.
NorGeno Tech & DNVGL are now members of the Oslo Cancer Cluster. Please find more information on the new members here.
Vi ønsker å komme i kontakt med medlemmer som har innspill til hvordan man kan legge til rette for enklere tilgang og bedre utnyttelse av helsedata.
Nordic Nanovector enters collaboration with Heidelberg Pharma GmbH to develop antobody drug conjugates for treating leukaemias.
RealKarriere is the Career Day for the The Faculty of Mathematics and Natural Sciences at University in Oslo. In 2017 the Career day will be arranged on February 9th 2017.
Kreftkostnader i Norge: Hvor ligger de største kostnadene? Hvilken kreftform er dyrest? Oslo Economics har utarbeidet en rapport om kostnadene ved kreft.
NCGC is joining forces with Norwegian Cancer Registry to establish a research platform for tumor-profiling in recruiting patients for clinical trials. They would like the help form members of the Oslo Cancer Cluster on what targets to include in the gene panel,
The Research Council is planning to announce up to NOK 45 million in funding for projects that promote value creation in the healthcare industry and is organising an applicant’s workshop on 24. October.
Nordic Nanovector ASA, is pleased to announce it has entered into a collaboration with LegoChem Biosciences, Inc. , a South Korea-based biopharmaceutical company, to develop novel CD37-targeting antibody-drug conjugates (ADCs) for the treatment of leukaemias.
December 15th is the date for the annual DNB HealthCare Conference. Be sure to apply for both the Health Care prize and to be a part of the Venture Session.
Over 50 people turned up for our R&D Network meeting on Precision Cancer Medicin at Stavanger University Hospital yesterday. The meeting was a collaboration beetween Oslo Cancer Cluster and Stavanger University Hospital(SUS) and was hosted by SUS.
Since IBM became a member of Oslo Cancer Cluster in June this year there has been a tremendous interest in their robot, Watson. The role of cognitive technology in cancer diagnostics has received attention both in national and international media.
Photocure ASA announced today that a study published on-line in the peer reviewed Journal of Urology, shows that there is no significant statistical difference in the frequency or grade of adverse events in patients having one Blue Light Cystoscopy with Cysview® (BLCC) versus repeat BLCC procedures.
Early September Oslo Cancer Cluster hosted an international press event with our member Abbvie. Over 20 journalists from all over Europe came to the Oslo Cancer Cluster Incubator and Innovatiion Park to learn more about the latest technological and scientific developments within cancer research. The journalists attended a full day meeting at the Innovation […]
The Nordic Life Science Days 2016 was a great success at many levels. For the first time the Norwegian life science actors invited to a joint meeting to promote a closer collaboration with the Swedish life science milieu at an event at the Norwegian Embassy in Stockholm.
Leading oncology biopharmaceutical company BerGenBio AS, today released important new preclinical study data on its first-in-class AXL inhibitor, BGB324.
Vicepresident Joe Biden used Norway as an example when he spoke at the Social Good Summit this week. Biden was appointed by Barack Obama to lead the “Cancer Moonshot” project. The project aims to make a decade’s worth of advances in cancer prevention, diagnosis, treatment, and care in just 5 years.
Artemida Pharma and Arctic Pharma are now members of the Oslo Cancer Cluster. Please find more information on the new members below. Arctic Pharma is also part of the Oslo Cancer Cluster Incubator.
Ketil Widerberg was interviewed alongside Jason Paragas from the Lawrence Livermore Research Laborator about the role of cooperation and supercomputers in finding breakthroughs in cancer prevention and treatment. You can see the interview here (in english) (forward to 16:47)
Photocure ASA announced today that data from the OPTIC III study: Optimized photodynamic diagnosis for transurethral resection of the bladder tumor (TURBT) in German clinical practice, is now available online in the World Journal of Urology. For more information see here.
PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company reported today an update on the phase I/II study in inoperable bile duct cancer patients.
Nordic Nanovector ASA (OSE: NANO) announces that two papers recently published in The Journal of Nuclear Medicine have shown that pre-dosing with the anti-CD37 antibody lilotomab (previously referred to as HH1), prior to injection with Betalutin® (177Lu-lilotomab) reduces haematological toxicity without adversely impacting the amount of radiation absorbed by the tumour.
Oslo Cancer Cluster member PCI Biotech is a cancer focused biopharmaceutical company. They have initiated a preclinical agreement with BioNTech AG which is a fully integrated biotechnology company developing individualized cancer immunotherapies.
5 students from Ullern High School do an intership at the Department of Molecular Pathology
On Wednesday 12th October 2016, the Netherlands Enterprise Agency, together with the EUREKA Secretariat and Enterprise Europe Network are organising an international event dedicated to the Eurostars programme (www.eurostars-eureka.eu) at the Amsterdam Arena in Amsterdam, the Netherlands.
Oslo Cancer Cluster and NCE Smart Energy Markets together with four European clusters in medicine and IT managed to land a prestigious Horizon 2020 EU project this spring. The official kick-off for the project is September 7th to 8th in Karlsrue and project manager Gupta Udatha is hired to work in both Oslo and Halden to implement the project from Norwegian side.
Inven2 has received NOK 6 mill from Innovation Norway to support Norwegian start-ups.
Oslo, Norway, August 29, 2016, Photocure ASA hosted on August 25 an educational event in New York aimed at institutional investors and analysts, which focused on the treatment of bladder cancer.
Det overordnede målet med Innovasjonsrammen 2016 er å stimulere til økt innovasjon gjennom flere felles innovasjons- og forskningsprosjekter mellom bedrifter.
Kreftvaksineselskapet Ultimovacs AS henter NOK 75 millioner til finansiering av videre kliniske studier. Selskapet har gjennomført tre vellykkede fase I-studier for sin terapeutiske vaksine mot kreft. Over 50 kreftpasienter har deltatt i studiene. Studiene viser at mer enn 80% av pasientene får aktivert sitt immunsystem som følge av denne behandlingen.
Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology, announces that the first cohorts of both Arm 3 and 4 of the expanded Lymrit 37-01 clinical study with Betalutin® have been completed.
New Cysview kit has an improved design providing healthcare professionals with an improved, simplified, and easy-to-use product
Oslo Cancer Cluster member PCI Biotech has received positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) for its lead product candidate, fimaporfin.
The International Journal of Cancer has recently published preclinical in vivo data in a mesothelioma xenograph model, demonstrating synergy of ONCOS-102 with pemetrexed and cisplatin, the current standard of care in malignant pleural mesothelioma.
Helseforskere kan få støtte til deltagelse i Horisont 2020 søknader fra to nye utlysninger:
Oslo 1 July 2016: Targovax today announced that the first patient has been dosed in a phase Ib/II clinical trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with pemetrexed and cisplatin.
Nordic Nanovector, a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, and AREVA Med, the AREVA medical subsidiary developing lead-212 (212Pb) based cancer therapies, announced today that they have entered into a collaboration agreement to investigate the potential of a 212Pb-conjugated anti-CD37 antibody for the treatment of leukaemias. Leukemias are orphan diseases with a significant unmet medical need. Prevalent relapsed AML and CLL patients are more than 60,000 per year worldwide. This represents a growing market worth over USD 5 billion by 2020.
The Oslo Cancer Cluster Incubator has recruited Nadine Lohs to be responsible for the operation of the Incubator from 1st August.
I sterk konkurranse fra 45 søkere har Inven2 fått tildelt NOK 6 mill av presåkornpotten for 2016 fra Innovasjon Norge.
Forskningsrådet har publisert utlysning av midler til postdoktor på kreftområdet med søknadsfrist 7. september 2016. Postdoktorperioden er totalt 3 år, hvorav de to første årene ved IARC i Lyon, Frankrike, og det siste året ved den norske søkerinstitusjonen.
EUs SMB-instrument i Horisont 2020 støtter testing og verifisering av disruptive innovasjoner. Meld deg på kurs hos Innovasjon Norge 16. juni i Oslo for å lære om hva du skal tenke på for å best beskrive din prosjektide og markedsplan i en søknad.
Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology announces that Luigi Costa, Chief Executive Officer, will hold a presentation at BIO International Convention in San Francisco, US on Tuesday 7 June 2016, at 3:30pm PDT in the room: Theater 1.
Targovax receives approval to conduct a study with TG02 and pembrolizumab, a checkpoint inhibitor, in patients with locally recurrent RAS mutated rectal cancer.
Erlend Strønen, Johanna Olweus and the Immunotherapy Jebsen Center team’s work on a breakthrough methodological development in generating broad and tumour-specific T-cell immune responses has been published in Science. The work is based on a novel allogeneic approach. This is a powerful technological development which can in the relatively near future be subjected to clinical testing.
Nordic Nanovector reports steady operational progress on Betalutin®’s clinical development plan in Follicular Lymphoma (FL), with recruitment of both sites and patients proceeding according to schedule. The Lymrit 37-01 study is on track to define the optimized dose regimen to be used in PARADIGME, the pivotal Phase 2 study planned to start in 2H 2017. Updated data from this ongoing clinical study, presented at the American Association of Cancer Research (AACR) in April, confirm Betalutin®’s efficacy potential, durability of response and favourable safety profile in patients with advanced FL.
Photocure ASA announced today new data from a prospective multicenter ongoing registry study that shows Blue Light Cystoscopy (BLC) with Cysview® increases detection rates of flat, more aggressive non-muscle invasive bladder cancer lesions (carcinoma in situ (CIS)) as well papillary lesions over white light cystoscopy (WLC) alone.
Nordic Nanovector ASA announces that the first patient has been enrolled into one of the two new arms of its expanded Lymrit 37-01 clinical study with Betalutin®.
The Norwegian Society for Immunology hosted their annual conference on the Day of Immunology on April 29. The theme for 2016 was Immunotherapy for Cancer. Below you may download some of the presentations as a courtesy of the lecturers.
Photocure ASA announced today the American Urological Association (AUA) and the Society of Urological Oncology (SUO) have included enhanced cystoscopy in the 2016 Guidelines for the management of non-muscle invasive bladder cancer (NMIBC).
Theodossis Theodossiou and Kristian Berg from the Photochemical internalisation (PCI) group at OUS have been funded by the Future and Emerging Technology (FET) program. The program funded 11 projects out of 820 grant applications, and the proposal by Theodossiou and Berg was rated as number 6.
The DoMore! project aims to explore the unique combination of academic and industrial competence within the project group to radically improve prognostication and hence treatment of cancer by using digital tools for pathology.
Photocure ASA is pleased to announce publication of a new analysis demonstrating that Blue Light Cystoscopy (BLC) with Hexvix/Cysview significantly prolonged time to disease progression and showed a trend in the reduction of the rate of progression in patients with non-muscle invasive bladder cancer (NMIBC). The data was published online in the April issue of the peer reviewed journal, Bladder Cancer.
Oslo Cancer Cluster will for the 5th time arrange International Cancer Cluster Showcase, ICCS in collaboration with leading cluster partners from Europe and North America. 20 oncology biotechs will pitch their latest innovations and partnering opportunities.
BerGenBio AS with preclinical data demonstrating that lead compound, BGB324, combined with immune checkpoint inhibitors has the potential to synergistically improve treatment of human cancers.
Nordic Nanovector with updated results of its ongoing Phase 1/2 study with Betalutin® in relapsed non-Hodgkin lymphoma (NHL) patients. Betalutin® was generally well tolerated and showed a 63.2% Overall Response Rate (ORR) including 31.6% Complete Response (CR) among 21 patients with previously treated CD37+ NHL patients.
Targovax has conducted an interim DTH immunological response evaluation assessing early immune activation following administration of TG01 in combination with gemcitabine in the ongoing Phase I/II trial. The results show that the modified and reduced vaccination schedule generated similar 8-week immune responses in patients with pancreatic cancer, as seen in the initial cohort.
The Immuno-Oncology Educational Series 2016 on April 6th featured cutting-edge presentations from leading Finnish and Norwegian clinicians and researchers within the field of cancer immunotherapy.
Nordic Nanovector ASA announces it has entered into a research and development collaboration programme with Paul Scherrer Institute (PSI) in Switzerland.
Contact us >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.